Regulus Therapeutics Inc. (NASDAQ:RGLS) shares rose 2.2% during trading on Tuesday . The company traded as high as $3.30 and last traded at $3.28, with a volume of 576,546 shares traded. The stock had previously closed at $3.21.

RGLS has been the topic of a number of research reports. BMO Capital Markets initiated coverage on Regulus Therapeutics in a research note on Monday, April 11th. They set an “outperform” rating and a $16.00 price target on the stock. Zacks Investment Research cut Regulus Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, May 6th. FBR & Co restated a “buy” rating and set a $30.00 price target on shares of Regulus Therapeutics in a research note on Thursday, June 2nd. Cowen and Company restated a “buy” rating on shares of Regulus Therapeutics in a research note on Wednesday, June 8th. Finally, Chardan Capital began coverage on Regulus Therapeutics in a research note on Wednesday, April 13th. They set a “buy” rating and a $15.00 price target on the stock. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $10.42.

The company’s 50-day moving average is $5.17 and its 200-day moving average is $6.41. The firm’s market cap is $183.68 million.

Regulus Therapeutics (NASDAQ:RGLS) last released its earnings results on Monday, May 2nd. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by $0.07. On average, equities research analysts expect that Regulus Therapeutics Inc. will post ($1.54) EPS for the current fiscal year.

A hedge fund recently bought a new stake in Regulus Therapeutics stock. Oxford Asset Management bought a new stake in Regulus Therapeutics Inc. (NASDAQ:RGLS) during the fourth quarter, according to its most recent filing with the SEC. The fund bought 260,798 shares of the biopharmaceutical company’s stock, valued at approximately $2,335,000. Oxford Asset Management owned approximately 0.50% of Regulus Therapeutics as of its most recent SEC filing.

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.